





RealRate

PHARMACEUTICAL 2021

Kiniksa Pharmaceuticals Ltd.
Rank 102 of 402



The relative strengths and weaknesses of Kiniksa Pharmaceuticals Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kiniksa Pharmaceuticals Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Kiniksa Pharmaceuticals Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 194%, being 146% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	333,249
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,846
Liabilities, Non-Current	5,683
Other Assets	12,164
Other Compr. Net Income	-67
Other Expenses	5,152
Other Liabilities	0
Other Net Income	1,134
Other Revenues	0
Property and Equipment	4,051
Research and Development	112,042
Selling, General and Administrative Expense	45,321

Output Variable	Value in 1000 USD
Assets	349,464
Liabilities	37,529
Expenses	162,515
Revenues	0
Stockholders Equity	311,935
Net Income	-161,381
Comprehensive Net Income	-161,414
Economic Capital Ratio	194%